Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA

Hasler and colleagues frame MDMA (3,4-methylenedioxymethamphetamine) as a drug whose primary action is to raise extracellular serotonin (5-HT) levels, with smaller contributions from dopamine and noradrenaline release. Previous animal and in vitro work implicates several serotonin receptor subtypes in MDMA’s effects, notably 5-HT2A receptors, and there is experimental evidence that MDMA can alter firing of serotonergic neurons via actions at somatodendritic 5-HT1A autoreceptors. However, the specific contribution of 5-HT1A receptors to MDMA’s subjective and cognitive effects in humans remained unclear. This study therefore set out to characterise acute MDMA effects on cognition, core dimensions of altered states of consciousness, mood and state anxiety in healthy volunteers, and to test whether antecedent blockade of 5-HT1A receptors with the mixed β-adrenoceptor/5-HT1A antagonist pindolol modulates those effects. Based on prior animal and mechanistic work, the investigators hypothesised that pindolol pre-treatment would attenuate or modulate MDMA-induced changes, particularly in affective domains and working memory.

Fifteen healthy male volunteers (mean age 24.3 ± 4.5 years, range 20–36) were recruited and screened medically and psychiatrically; exclusion criteria included personal or family history of psychiatric disorder and extreme scores on personality subscales that predict negative experiences with altered states. Most participants were drug-naive or reported only occasional prior use of cannabis or single past experiences with MDMA or hallucinogens. All provided informed consent and the protocol received ethical and regulatory approval. The study used a double-blind, placebo-controlled, within-subject repeated-measures design with counter-balanced order and at least two weeks between sessions. Each subject completed four conditions: placebo-placebo (PLA), pindolol-placebo (PIN), placebo-MDMA (MDMA), and pindolol-MDMA (PIN-MDMA). Pindolol (20 mg oral) or placebo was given at the start of the study day, and one hour later MDMA (1.6 mg/kg body weight, mean absolute dose 122 ± 14 mg) or placebo was administered. Vital signs were monitored every 30 minutes and subjects remained in the unit until psychotropic and cardiovascular effects subsided. Primary psychometric assessments included the 5D-ASC (5 Dimensions of Altered States of Consciousness) collected 210 minutes after the first medication to capture retrospective ratings of the experience; the Adjective Mood Rating Scale (AMRS) at 5, 135, 170 minutes and 24 hours; and the State-Trait Anxiety Inventory state scale (STAI X1) at the same repeated time points. Cognitive testing used three CANTAB tasks administered 180 minutes after pre-treatment: Rapid Visual Information Processing (RVP) for sustained attention and vigilance, Paired Associates Learning (PAL) for visuospatial memory, and Intradimensional/Extradimensional shift (ID/ED) for executive function and set shifting. Subjects received training on CANTAB tasks during screening and different stimulus sets were used across sessions where available. Statistical analysis employed univariate repeated-measures analysis of variance (ANOVA) with within-subject factors of pre-treatment (PLA vs PIN) and treatment (PLA vs MDMA) for the 5D-ASC, AMRS and CANTAB measures. STAI X1 scores were analysed with two-way repeated-measures ANOVA (medication × rating time). Significant ANOVA effects were followed by Tukey HSD post hoc tests. The significance threshold was p < 0.05. (A repeated-measures ANOVA assesses within-subject differences across conditions while accounting for correlations between repeated measurements.)

Fifteen participants completed all four conditions. MDMA produced robust subjective effects consistent with the entactogen profile: marked increases in mood, self-awareness, feelings of empathy and positive derealization, and moderate increases in perceptual intensification without complex psychedelic hallucinations. On the 5D-ASC, MDMA significantly increased scores across the principal dimensions, and AMRS subscales for heightened mood, excitability, sensitivity and dreaminess were elevated under MDMA compared with placebo. Cognitive testing showed domain-specific impairments under MDMA. On the RVP sustained-attention task, MDMA significantly reduced total hits (RVP-TH) and sensitivity (RVP-A') and increased response latency (RVP-ML) compared with placebo; these differences reached p < 0.01 for RVP-TH and RVP-A'. Visuospatial memory assessed by the PAL task was also impaired: PAL total errors (PAL-TE) and trials to criterion (PAL-TT) were significantly higher under MDMA (p < 0.01). By contrast, the ID/ED task of executive function showed no significant main effects of treatment on extradimensional shift errors, pre-EDS errors or stages completed. Pre-treatment with 20 mg pindolol did not materially alter the MDMA-induced cognitive impairments: performance on RVP and PAL under PIN-MDMA did not differ significantly from MDMA alone, although RVP-TH remained significantly lower under PIN-MDMA versus placebo (p < 0.05). For executive measures, no main effects of pre-treatment nor pre-treatment × treatment interactions were observed. At the psychometric level, pindolol had only minor modulatory effects: PIN reduced MDMA-induced positive derealization on the 5D-ASC Oceanic Boundlessness (OB) dimension, driven mainly by decreases in 'positive basic mood' and 'mania-like experience', and PIN lowered scores on the AMRS 'dreaminess' subscale. All other MDMA-evoked psychometric changes were not significantly affected by pindolol. State anxiety analysis produced a significant main effect of medication [F(3,42)=5.16; p < 0.01], but pairwise post hoc tests did not show significant differences at any specific rating time. No acute adverse psychiatric reactions (e.g. severe anxiety, panic or paranoia) were observed, and cardiovascular/physical safety monitoring did not yield safety concerns reported in the extracted text. Correlational analyses showed negative associations between sustained-attention performance and phenomenological measures: higher scores on 5D-ASC subscales 'facilitated imagination' and 'facilitated recollection' correlated with worse RVP performance (r = -0.54 and r = -0.57 respectively, p < 0.05), and AMRS 'dreaminess' also negatively correlated with RVP performance (r = -0.57, p < 0.05).

Hasler and colleagues interpret the findings as confirming that a moderate recreational dose of MDMA reliably produces an entactogen-like subjective state—heightened mood, increased empathy and positive derealization—together with selective cognitive impairments. The investigators emphasise that MDMA markedly impaired sustained attention and visuospatial memory while leaving the tested aspects of executive function (attentional set shifting) intact. Correlations between increased imagery/recollection and poorer vigilance support the idea that heightened internal cognitive content may interfere with maintaining attention over extended periods. With respect to the central question about 5-HT1A receptors, antecedent blockade with 20 mg pindolol produced only minor changes in subjective experience and did not significantly attenuate MDMA-induced cognitive deficits. From these results the authors conclude that their data do not support a major causal role for 5-HT1A receptor stimulation in mediating the core subjective and cognitive effects of MDMA in humans. They note, however, several important caveats and uncertainties: a single 20 mg oral dose of pindolol yields only about 40% occupancy of pre- and postsynaptic 5-HT1A receptors according to a referenced PET study, so incomplete receptor blockade could have masked effects; higher pindolol doses were avoided because of β-adrenergic side effects and concerns about peripheral haemodynamic reactions if β-blockade were unopposed. The MDMA dose may also have been high relative to the antagonist dose, producing very large increases in extracellular 5-HT that could overcome partial receptor blockade. The authors further point out that animal data on 5-HT1A involvement in MDMA effects are inconsistent, and that differences in species, antagonist selectivity and dosing complicate comparisons. They recommend further mechanistic receptor-blocking studies using different antagonists and dosing regimens, including higher or multiple doses of pindolol and selective 5-HT1A agonists/antagonists, to clarify the contribution of 5-HT1A receptors to MDMA’s psychopharmacology. Limitations acknowledged in the paper include the modest sample size, the healthy male-only sample, partial receptor occupancy by pindolol and potential confounding from pindolol’s beta-adrenoceptor activity.